gRNA市场－全球产业规模、份额、趋势、机会和预测，按类型、产品和服务（产品、客製化gRNA合成服务）、应用、最终用途、地区和竞争格局划分，2020-2030年预测

2024年全球gRNA市场规模为5.59亿美元，预计2030年将以19.20%的复合年增长率成长至16.0352亿美元。引导RNA（gRNA）是一种合成RNA分子，是CRISPR-Cas9基因编辑系统的关键组成部分，能够精确引导Cas9核酸酶标靶特定的DNA序列进行修饰。全球gRNA市场的成长主要得益于基因编辑技术的显着进步、全球遗传疾病盛行率的上升导致对新型基因疗法的需求增加，以及gRNA在生物医学研究和农业领域应用范围的不断扩大。对生物技术研发的大量投资也进一步推动了市场扩张。

主要市场驱动因素

全球gRNA市场的扩张主要得益于CRISPR-Cas基因编辑系统的广泛应用，而gRNA分子正是这项基础技术的关键组成部分。 CRISPR疗法的临床验证和商业化进程不断推进，正是这一应用趋势的有力佐证。

主要市场挑战

全球监管环境的复杂性和异质性对全球gRNA市场的成长构成重大阻碍。各国和各地区的法规差异导致产品审批流程繁琐且往往重复，直接推高了研发成本，并延长了商业化进程。

主要市场趋势

符合GMP标准的gRNA的出现，标誌着基因编辑技术从研究阶段转向治疗产品阶段的转变，也因此对gRNA分子提出了严格的良好生产规范（GMP）要求。这确保了进入临床试验和市场应用的基因疗法的安全性、纯度和有效性。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球gRNA市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型（科研用、GMP级）
  • 按产品和服务分类（产品、客製化gRNA合成服务）
  • 依应用领域（基因组工程、疾病模型研究、功能基因体学、表观遗传学、其他）
  • 按最终用途划分（製药和生物技术公司、学术研究机构、合约生产组织和合约研究组织）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美gRNA市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲gRNA市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区gRNA市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲gRNA市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美gRNA市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球gRNA市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• System Biosciences, LLC
• Jena Bioscience GmbH
• Merck KGaA
• Azenta US, Inc.
• Takara Bio, Inc.
• Synbio Technologies
• Revvity, Inc.
• Synthego Corporation

第十六章：策略建议

第17章调查会社について・免责事项

The Global gRNA Market, valued at USD 559.00 Million in 2024, is projected to experience a CAGR of 19.20% to reach USD 1603.52 Million by 2030. Guide RNA (gRNA) is a synthetic RNA molecule serving as a pivotal component within the CRISPR-Cas9 genome editing system, precisely directing the Cas9 nuclease to target specific DNA sequences for modification. The global gRNA market's growth is primarily driven by significant advancements in gene editing technologies, the increasing global prevalence of genetic disorders leading to higher demand for novel gene therapies, and expanding applications across biomedical research and agriculture. Substantial investment in biotechnology research and development further propels market expansion.

Key Market Drivers

The global gRNA market's expansion is significantly propelled by the widespread adoption of CRISPR-Cas systems for gene editing, a foundational technology that gRNA molecules directly enable. The increasing clinical validation and commercialization of CRISPR-based therapies exemplify this adoption. For instance, according to Vertex's Q3 2024 financial report, 40 individuals have entered the treatment process for Casgevy, the first approved CRISPR-based medicine, demonstrating tangible progress in patient access and therapeutic application.

Key Market Challenges

The complex and heterogeneous global regulatory landscape represents a significant impediment to the growth of the Global gRNA Market. Diverse national and regional regulations necessitate extensive and often duplicative processes for product approval, directly escalating development costs and extending timelines for commercialization. This regulatory fragmentation consumes substantial financial and human resources, which could otherwise be directed towards scientific innovation and market penetration. The inherent uncertainty and varying requirements across jurisdictions also deter investment, particularly from smaller entities, thereby limiting the pipeline of novel gRNA-based applications.

Key Market Trends

The emergence of GMP-grade gRNA for clinical applications represents a pivotal shift as gene editing technologies transition from research to therapeutic products, necessitating stringent Good Manufacturing Practice standards for gRNA molecules. This ensures the safety, purity, and efficacy of gene therapies entering trials and the market. The escalating pipeline of gene therapy candidates directly fuels demand for high-quality gRNA manufacturing solutions.

Key Market Players

• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• System Biosciences, LLC
• Jena Bioscience GmbH
• Merck KGaA
• Azenta US, Inc.
• Takara Bio, Inc.
• Synbio Technologies
• Revvity, Inc.
• Synthego Corporation

Report Scope:

In this report, the Global gRNA Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

gRNA Market, By Type:

• Research-Use
• GMP-grade

gRNA Market, By Product & Services:

• Product
• Custom gRNA Synthesis Services

gRNA Market, By Application:

• Genome Engineering
• Disease Model Studies
• Functional Genomics
• Epigenetics
• Others

gRNA Market, By End Use:

• Pharmaceutical & Biotechnology Companies
• Academic Research Institutes
• CMOs & CROs

gRNA Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global gRNA Market.

Available Customizations:

Global gRNA Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global gRNA Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Research-Use, GMP-grade)
  • 5.2.2. By Product & Services (Product, Custom gRNA Synthesis Services)
  • 5.2.3. By Application (Genome Engineering, Disease Model Studies, Functional Genomics, Epigenetics, Others)
  • 5.2.4. By End Use (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, CMOs & CROs)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America gRNA Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product & Services
  • 6.2.3. By Application
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States gRNA Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product & Services
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada gRNA Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product & Services
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico gRNA Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product & Services
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe gRNA Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product & Services
  • 7.2.3. By Application
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany gRNA Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product & Services
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. France gRNA Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product & Services
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom gRNA Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product & Services
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy gRNA Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product & Services
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain gRNA Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product & Services
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia Pacific gRNA Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product & Services
  • 8.2.3. By Application
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China gRNA Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product & Services
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. India gRNA Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product & Services
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan gRNA Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product & Services
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea gRNA Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product & Services
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia gRNA Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product & Services
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. Middle East & Africa gRNA Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product & Services
  • 9.2.3. By Application
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia gRNA Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product & Services
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE gRNA Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product & Services
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa gRNA Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product & Services
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. South America gRNA Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product & Services
  • 10.2.3. By Application
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil gRNA Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product & Services
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia gRNA Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product & Services
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina gRNA Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product & Services
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global gRNA Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies, Inc.
• 15.3. System Biosciences, LLC
• 15.4. Jena Bioscience GmbH
• 15.5. Merck KGaA
• 15.6. Azenta US, Inc.
• 15.7. Takara Bio, Inc.
• 15.8. Synbio Technologies
• 15.9. Revvity, Inc.
• 15.10. Synthego Corporation

16. Strategic Recommendations

17. About Us & Disclaimer